Pharvaris N.V. (PHVS)
NasdaqGS · USD · Healthcare · Biotechnology
$31.54 (+0.41%) as of
Key statistics
- Market cap
- 2.21B
- Forward P/E
- -10.32
- EPS (TTM)
- -3.06
- Dividend yield
- 0.00%
- 52-week range
- 21.02 – 43.25
- Beta
- -2.46
- Profit margin
- 0.00%
- Analyst target
- $57.42
- Volume
- 347.29k
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zug, Switzerland
- Employees
- 148
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.